Five High-Value Healthcare Startups with Avg. Funding Over $140M to Showcase in Joint Roadshow

For most startups, venture capital is crucial, yet it remains difficult for high-potential companies to find discerning investors. Similarly, investment institutions face significant challenges in making successful bets with low trial-and-error costs. To bridge this gap, the Shenzhen Stock Exchange and the Torch High Technology Industry Development Center of the Ministry of Science and Technology jointly established the SZSE Innovation and Entrepreneurship Investment and Financing Service Platform (V-Next).The platform curates a selection of high-quality projects that have secured one or more rounds of financing for roadshows, assisting venture capital and private equity firms in strengthening post-investment portfolio management and exit strategies, while broadening their channels for collaboration with listed companies and other investment institutions.Providing comprehensive services for the corporate venture capital and M&A markets.

VCBeat (WeChat ID: vcbeat) has learned thatOn May 16, V-Nex, in collaboration with Legend Capital and Shanghai Industrial Investment (Group) Co., Ltd., hosted a dedicated roadshow for high-quality healthcare projects backed by Legend Capital. The event featured five premium companies spanning the fields of biopharmaceuticals, artificial intelligence, and medical devices. All projects presented were at Series C or later stages of financing, with an average disclosed funding amount exceeding RMB 100 million. In addition to Legend Capital, these companies have received investment and endorsement from multiple renowned institutional investors.The roadshow project will be held from 14:00 to 15:55 on May 16 at the CIDI Innovation Experience Center, Building 3, Chuangzhi Technology Center, No. 477 Zhengli Road, Yangpu District, Shanghai.

Currently, the Shenzhen Stock Exchange’s Innovation and Entrepreneurship Investment and Financing Service Platform has successively partnered with over 50 institutions—including Shenzhen Capital Group, Fortune Capital, Cowin Capital, Oriental Fortune Capital, Sinoway Capital, Zheshang Venture Capital, China Ventures, China Merchants Capital, Ausino Capital, Shanghai International Venture Capital & Management Corporation, Qifu Capital, Entertainment Works, Innovation Works, High-Tech Investment, Lihetouzi, Hechuang Capital, Ziniu Fund, and Mingshi Capital—to launch specialized post-investment roadshow events, and has signed strategic cooperation agreements with multiple institutions.

As a top-tier investment firm in China, Legend Capital is a professional institution under Legend Holdings, specializing in venture capital for start-ups and growth equity for expanding companies. Currently, the total assets under management of its USD and RMB funds exceed RMB 40 billion, with a primary focus on innovation and growth opportunities in China. As of 2017, Legend Capital had invested in nearly 400 portfolio companies, among which approximately 70 have successfully gone public or been listed on domestic or overseas stock exchanges, and nearly 50 have achieved exits through mergers and acquisitions.

At this Legend Capital post-investment special event, all five featured companies operate in the healthcare sector, with core businesses spanning wearable real-time continuous glucose monitoring systems, AI-powered medical imaging platforms, innovative drug development for metabolic syndrome, and ambulatory surgery centers. According to the currently released profiles, each company has achieved notable progress in its respective niche market. At the roadshow, the founders of these five companies will provide detailed presentations. Here, we offer a preliminary glimpse into their project summaries.

Among them, the project company for the wearable real-time continuous glucose monitoring system is a Sino-foreign joint venture engaged in the research, development, and manufacturing of medical devices, established in 2010. Currently employing over 80 staff members, the company is dedicated to the development and production of highly integrated medical monitoring devices centered on biosensor core technology.

The company’s CT-100 Continuous Glucose Monitoring (CGM) System represents a new generation of real-time CGM solutions. Its sensor features a unique four-electrode system that monitors background variations and interference signals in real time, enabling real-time correction of glucose readings for enhanced reliability. The four-electrode sensor is integrated onto an ultra-thin flexible substrate, ensuring comfortable wear and minimal irritation to subcutaneous tissue. The innovative sensor-applicator design incorporates a proprietary adjustable insertion angle, which optimizes utilization of the subcutaneous tissue layer and increases the effective electrode surface area, resulting in a high signal-to-noise ratio. Clinical studies have demonstrated its superior stability. Furthermore, the CGM system utilizes Bluetooth Low Energy (BLE) technology to enable multi-platform data sharing, including with smartphones. The product is currently being sold in European Union countries, where early market acceptance has exceeded expectations, and sales are expanding steadily. It is expected to launch in China next year.

The core advantage of the project company’s technical products lies in its biosensor technology. Its dynamic continuous glucose monitoring system holds independent intellectual property rights. After obtaining CE certification, the product has gained recognition from multiple international brand companies, many of which have sought agency and collaboration opportunities. Currently, it has entered the sales phase in the European Union market, with performance and cost-effectiveness that are internationally competitive.. It has currently entered the initial phase of global sales and, together with international partners, has advanced to the development stage for next-generation products, targeting the global diabetes market.

The company secured its Series A financing in 2014, establishing initial strategic partnerships with three venture capital firms: Legend Capital, Shanghai Kailian Medical, and Hong Kong-based Lenomed. In 2017, it completed its Series B financing, bringing in YuanSheng Venture Capital, Tasly Capital, and Tonghua Dongbao, thereby forging a powerful alliance. This has made the company a model of collaboration between an internationally seasoned technical and management team and outstanding domestic capital.

The AI Imaging Platform project company is a leading tech-medical platform in China. By deeply integrating medical technology with artificial intelligence, it provides precise diagnosis and long-term disease management services for patients in key specialties, while offering physicians a professional practice platform.It is also the first company in China to hold qualifications for both an online internet hospital and offline physical imaging centers. Its online internet hospital platform covers nearly 50,000 physicians, while its offline imaging centers are distributed across 17 provinces and municipalities, with cumulative patient medical records exceeding 8.5 million. In 2018, its revenue increased by nearly threefold year-on-year, and its net profit margin exceeded 10%.The company has received investments from renowned institutions such as CICC Capital, Matrix Partners China, Legend Capital, and Lenovo Star.

This tech-healthcare platform adopts a unique model: China’s first integrated platform combining an online internet hospital with offline imaging centers. By integrating asset-light and asset-heavy operations, it empowers medical services through imaging and AI, thereby enhancing clinical diagnostic accuracy and operational efficiency. The platform offers exclusive diagnostic products surpassing the standards of top-tier (Grade 3A) hospitals: It has developed 38 proprietary diagnostic solutions focused on key specialized diseases such as oncology and cardiovascular/cerebrovascular disorders, which have been endorsed by leading clinical experts across China.

The company is a biopharmaceutical enterprise dedicated to researching and developing innovative drug products for the global market, addressing unmet clinical and market needs in metabolic diseases. Leveraging its independent R&D capabilities, the company has developed a series of innovative drugs targeting metabolic syndrome, including diabetes, obesity, non-alcoholic steatohepatitis (NASH), and gout. Its core product pipeline, featuring PB-119 (a GLP-1 receptor agonist), PB-718 (a dual GLP-1 and GCG receptor agonist), PB-201 (a glucokinase activator), and PB-815 (a recombinant uricase), covers various metabolic disorders such as type 2 diabetes, obesity, NASH, and hyperuricemia (gout). The company has secured global invention patents for these novel compounds and is conducting clinical trials at different stages worldwide. For instance, PB-119 is about to complete Phase II clinical trials in both China and the United States and is expected to enter global Phase III clinical trials this year; PB-201 has already completed global Phase II clinical trials. Building on these products, the company will continue to develop targets that synergize with existing products and other therapeutic agents through internal innovative R&D and external collaborations, thereby enriching its product pipeline and providing diverse effective treatment options for patients globally. The market potential for metabolic disease drugs is substantial; PB-119 is projected to have a market potential of RMB 4 billion in China, while PB-718 is estimated to have a global market potential of USD 5 billion.

As the only domestic biopharmaceutical company specializing in metabolic diseases, the Company is collaborating with domestic and international securities firms to file for an initial public offering (IPO) on the Main Board of The Stock Exchange of Hong Kong Limited, with listing expected to be completed within the next year.

The company has received investment from ten renowned institutions, including Legend Capital, China Growth Capital, Lenovo Star Ventures, Yuanhe Venture Capital, Yuansheng Venture Capital, Kaifeng Venture Capital, Tigermed Fund, Shenzhen Qianhai Fund of Funds, and Tasly Holding.

As the pioneer of premium chained ambulatory surgery centers in China, the project company is a boutique medical institution offering comprehensive healthcare services, with established locations in the central areas of both Pudong and Puxi in Shanghai. The company provides general practice and multi-specialty medical services, specializing in minimally invasive surgeries. It is equipped with advanced and complete diagnostic facilities and features Class 100 laminar flow operating rooms that meet high cleanliness standards. Furthermore, the company has partnered with mainstream commercial insurers to build a professional, convenient, harmonious, and reassuring medical service platform. Its physicians hail from around the world, providing multilingual services in English, Japanese, Korean, and Chinese.

The one-stop medical equipment management solution focuses on providing Chinese healthcare institutions with comprehensive equipment management solutions, precise equipment maintenance, regular equipment asset assessments and recommendations, specialized training for healthcare professionals on equipment maintenance and usage, as well as ongoing management and technical support. As domestic health insurance cost-containment policies deepen, hospitals will increasingly adopt outsourcing of cost items to achieve effective cost control, with equipment maintenance outsourcing emerging as a key direction. By leveraging its self-developed mobile applications and intelligent platform, the company enables full lifecycle management, data-driven management, and intelligent monitoring of medical equipment. As one of the first pioneers in China to propose independent third-party outsourcing solutions for hospital equipment, the project company is poised to play a significant role in the ongoing transformation of large-scale equipment maintenance models in the country.

Currently, 80% of the platform’s patients come from word-of-mouth referrals. The number of minimally invasive surgical procedures offered has exceeded 100 types, with both surgical and outpatient volumes continuing to rise and reach new highs. The platform has already enabled direct billing with over 100 commercial insurance providers and will continue to expand and deepen its insurance partnerships, thereby broadening its reach.The company has successively received investments from renowned institutions, including Licheng Asset Management, Legend Capital, Zhengqi Finance, Licheng Asset Management, the Medtronic China Fund, and Yuanjing Capital.

It is reported that the entire roadshow will be conducted throughwww.chinahtz.com and the “Flint Spark” APP provide live video streaming to venture capital firms, listed companies, and other institutions across China.Professional equity investment institutions and listed companies interested in attending the event in person may also register by scanning the QR code below.